Albany, NY -- (SBWIRE) -- 09/03/2019 -- Bullous Pemphigoid Market Insights, Epidemiology and Market Forecast-2028
1. Incidence of all autoimmune bullous diseases to be around 66 cases per million people per year in Germany, UK, France, Italy, and the US.
2. Bullous Pemphigoid is the most common type of subepidermal autoimmune bullous diseases.
3. Bullous Pemphigoid highest incidences occur in the population older than 80 years of age, i.e., 150–300 cases per million people.
DelveInsight launched a new report on Bullous Pemphigoid Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Bullous Pemphigoid market report covers a descriptive overview and comprehensive insight of the Bullous Pemphigoid epidemiology and Bullous Pemphigoid market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Bullous Pemphigoid market report provides insights on the current and emerging therapies.
3. Bullous Pemphigoid market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Bullous Pemphigoid market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Bullous Pemphigoid market.
Request for sample pages
"Bullous Pemphigoid estimated incidence ranges from 2.8 per 100,000 persons/year in the US to 4.28 per 100,000 persons per year in the UK and most commonly presenting in people over 80 years old."
Bullous pemphigoid therapeutic options have been transformed significantly in the past decade. Currently, Bullous pemphigoid market size is dominated by corticosteroids (either in pill or topical form), antibiotics, and other anti-inflammatory drugs, which are used as the first line of treatment. Corticosteroids are combined with an immunosuppressive adjuvant to minimize the adverse effects of chronic corticosteroid therapy. The immunosuppressant includes azathioprine, mycophenolate, methotrexate, dapsone, cyclosporin, cyclophosphamide, etc., antibiotics include Tetracycline derivatives, such as minocycline or doxycycline, erythromycin, and nicotinamide are used as Bullous pemphigoid therapeutic choices. However, these therapies may be associated with serious adverse effects, like weight gain, high blood pressure, and sometimes deaths. Currently, there is only one drug, i.e., Kenketsu GLOVENIN-I (NPB-01; Nihon Pharmaceutical) for I.V. injection that has been approved in Japan for Bullous pemphigoid treatment. It is a lyophilized powder for solution for injection containing freeze-dried polyethylene glycol-treated human normal immunoglobulin G as the active ingredient. The usual dosage of human immunoglobulin G is 400 mg (in 8 mL)/kg body weight administered once daily for 5 consecutive days by an intravenous infusion. In the era of biological therapies, new antibody modulators, including rituximab and omalizumab, have been suggested for Bullous pemphigoid treatment, with detection of tissue-bound and circulating autoantibodies, in most of the Bullous pemphigoid patients. However, further large scale studies are required to recommend them.
The Bullous pemphigoid market is expected to grow in the coming years due to escalating geriatric population and increased life expectancy over the globe surge chances of incidence of disease and thus the surge in Bullous pemphigoid treatment options. Common and non-expensive medication uses in Bullous pemphigoid treatment is driving Bullous pemphigoid treatment market. Furthermore, various awareness programs by healthcare organizations and NGOs support the rise of Bullous pemphigoid treatment market for the forecast period.
The launch of the emerging therapies is expected to significantly impact the Bullous pemphigoid treatment scenario in the upcoming years:-
Drugs covered
1. Bertilimumab
2. Coversin
3. AC-203
And many others
The key players in Bullous pemphigoid market are:
1. Immune Pharmaceuticals
2. Akari Therapeutics
3. TWi Biotechnology
4. Eli Lilly and Company
And many others
Table of contents
1. Report Introduction
2. Bullous Pemphigoid Market Overview at a Glance
3. Bullous Pemphigoid Disease Background and Overview
4. Bullous Pemphigoid Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Incident Cases of Bullous Pemphigoid (2017–2028)
4.4. Total Patient Population of Bullous Pemphigoid by Regions
4.4.1.United States
4.4.2.EU5
4.4.2.1. Germany
4.4.2.2. Italy
4.4.2.3. Spain
4.4.2.4. France
4.4.2.5. United Kingdom
4.4.3.Japan
5. Bullous Pemphigoid Current Treatment and Medical Practices
6. Bullous Pemphigoid Unmet Needs
7. Bullous Pemphigoid Marketed drugs
7.1. Kenketsu GLOVENIN-I (NPB-01): Nihon Pharmaceuticals
8. Bullous Pemphigoid Emerging Therapies
8.1. Key Cross Competition
8.2. Bertilimumab: Immune Pharmaceuticals
8.3. Coversin: Akari Therapeutics
9. Bullous Pemphigoid Market Outlook
10. 7MM: Country-Wise Market Analysis (2017–2028)
10.1.United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. United Kingdom Market Size
10.5. Spain Market Size
10.6. Italy Market Size
10.7. Japan
11. Market drivers
12. Market barriers
13. Appendix
14. Bullous Pemphigoid Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight